In particular, 16.7% of patients with 1L CPI therapy showed an ongoing response upon 1L CPI therapy, whereas only 7.9% of patients treated with 1L BRAF ± MEKi did not experience tumor progression at any time during the follow-up period (see Figure 1). This evidence concerns the gene BRAF and neoplasm.